Abstract
Erythrina sp. contains alkaloids and flavonoids, which are the primary bioactive compounds found in these species. These organisms are a rich source of secondary metabolites. Two known pterocapans in this study, eryvarin D (1) and eryvarin E (2), were successfully isolated from the root bark extract of Erythrina variegata. The isolated compounds were elucidated using 1D- and 2D-NMR spectroscopy. Among the two compounds, only compound 2 was evaluated for its inhibitory activity against eight receptor tyrosine kinases (EGFR, HER2, HER4, IGFR, InsR, KDR, PDGFRα, and PDGFRβ). Compound 2 exhibited weak insulin receptor inhibitory activity. Thus, compound 2 could be a lead compound as an anticancer drug targeting insulin receptors for future development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.